Pharmacological and Biological Targeting of FGFR1 in Cancer

Shuai Fan; Yuxin Chen; Wenyu Wang; Wanting Xu; Mei Tian; Yuetong Liu; Yutong Zhou; Dan Liu; Qin Xia; Lei Dong

doi:10.3390/cimb46110783

Pharmacological and Biological Targeting of FGFR1 in Cancer

Shuai Fan, Yuxin Chen, Wenyu Wang, Wanting Xu, Mei Tian, Yuetong Liu, Yutong Zhou, Dan Liu, Qin Xia^*, Lei Dong^*

^*此作品的通讯作者

生命学院

Beijing Institute of Technology

科研成果: 期刊稿件 › 文献综述 › 同行评审

1 引用（Scopus）

摘要

FGFR1 is a key member of the fibroblast growth factor receptor family, mediating critical signaling pathways such as RAS-MAPK and PI3K-AKT. which are integral to regulating essential cellular processes, including proliferation, differentiation, and survival. Alterations in FGFR1 can lead to constitutive activation of signaling pathways that drive oncogenesis by promoting uncontrolled cell division, inhibiting apoptosis, and enhancing the metastatic potential of cancer cells. This article reviews the activation mechanisms and signaling pathways of FGFR1 and provides a detailed exposition of the types of FGFR1 aberration. Furthermore, we have compiled a comprehensive overview of current therapies targeting FGFR1 aberration in cancer, aiming to offer new perspectives for future cancer treatments by focusing on drugs that address specific FGFR1 alterations.

源语言	英语
页（从-至）	13131-13150
页数	20
期刊	Current Issues in Molecular Biology
卷	46
期	11
DOI	https://doi.org/10.3390/cimb46110783
出版状态	已出版 - 11月 2024

联合国可持续发展目标

此成果有助于实现下列可持续发展目标：

访问文件

10.3390/cimb46110783

其它文件与链接

链接到 Scopus 的出版物

引用此

Fan, S., Chen, Y., Wang, W., Xu, W., Tian, M., Liu, Y., Zhou, Y., Liu, D., Xia, Q., & Dong, L. (2024). Pharmacological and Biological Targeting of FGFR1 in Cancer. Current Issues in Molecular Biology, 46(11), 13131-13150. https://doi.org/10.3390/cimb46110783

@article{1ba82b27f50a4ccaac9ceffacd9af43f,

title = "Pharmacological and Biological Targeting of FGFR1 in Cancer",

abstract = "FGFR1 is a key member of the fibroblast growth factor receptor family, mediating critical signaling pathways such as RAS-MAPK and PI3K-AKT. which are integral to regulating essential cellular processes, including proliferation, differentiation, and survival. Alterations in FGFR1 can lead to constitutive activation of signaling pathways that drive oncogenesis by promoting uncontrolled cell division, inhibiting apoptosis, and enhancing the metastatic potential of cancer cells. This article reviews the activation mechanisms and signaling pathways of FGFR1 and provides a detailed exposition of the types of FGFR1 aberration. Furthermore, we have compiled a comprehensive overview of current therapies targeting FGFR1 aberration in cancer, aiming to offer new perspectives for future cancer treatments by focusing on drugs that address specific FGFR1 alterations.",

keywords = "FGFR1, TKI, aberration, antibody drugs, ligand traps, targeted therapeutics",

author = "Shuai Fan and Yuxin Chen and Wenyu Wang and Wanting Xu and Mei Tian and Yuetong Liu and Yutong Zhou and Dan Liu and Qin Xia and Lei Dong",

note = "Publisher Copyright: {\textcopyright} 2024 by the authors.",

year = "2024",

month = nov,

doi = "10.3390/cimb46110783",

language = "English",

volume = "46",

pages = "13131--13150",

journal = "Current Issues in Molecular Biology",

issn = "1467-3037",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "11",

}

TY - JOUR

T1 - Pharmacological and Biological Targeting of FGFR1 in Cancer

AU - Fan, Shuai

AU - Chen, Yuxin

AU - Wang, Wenyu

AU - Xu, Wanting

AU - Tian, Mei

AU - Liu, Yuetong

AU - Zhou, Yutong

AU - Liu, Dan

AU - Xia, Qin

AU - Dong, Lei

PY - 2024/11

Y1 - 2024/11

N2 - FGFR1 is a key member of the fibroblast growth factor receptor family, mediating critical signaling pathways such as RAS-MAPK and PI3K-AKT. which are integral to regulating essential cellular processes, including proliferation, differentiation, and survival. Alterations in FGFR1 can lead to constitutive activation of signaling pathways that drive oncogenesis by promoting uncontrolled cell division, inhibiting apoptosis, and enhancing the metastatic potential of cancer cells. This article reviews the activation mechanisms and signaling pathways of FGFR1 and provides a detailed exposition of the types of FGFR1 aberration. Furthermore, we have compiled a comprehensive overview of current therapies targeting FGFR1 aberration in cancer, aiming to offer new perspectives for future cancer treatments by focusing on drugs that address specific FGFR1 alterations.

AB - FGFR1 is a key member of the fibroblast growth factor receptor family, mediating critical signaling pathways such as RAS-MAPK and PI3K-AKT. which are integral to regulating essential cellular processes, including proliferation, differentiation, and survival. Alterations in FGFR1 can lead to constitutive activation of signaling pathways that drive oncogenesis by promoting uncontrolled cell division, inhibiting apoptosis, and enhancing the metastatic potential of cancer cells. This article reviews the activation mechanisms and signaling pathways of FGFR1 and provides a detailed exposition of the types of FGFR1 aberration. Furthermore, we have compiled a comprehensive overview of current therapies targeting FGFR1 aberration in cancer, aiming to offer new perspectives for future cancer treatments by focusing on drugs that address specific FGFR1 alterations.

KW - FGFR1

KW - TKI

KW - aberration

KW - antibody drugs

KW - ligand traps

KW - targeted therapeutics

UR - http://www.scopus.com/inward/record.url?scp=85210429977&partnerID=8YFLogxK

U2 - 10.3390/cimb46110783

DO - 10.3390/cimb46110783

M3 - Review article

AN - SCOPUS:85210429977

SN - 1467-3037

VL - 46

SP - 13131

EP - 13150

JO - Current Issues in Molecular Biology

JF - Current Issues in Molecular Biology

IS - 11

ER -

Pharmacological and Biological Targeting of FGFR1 in Cancer

摘要

联合国可持续发展目标

访问文件

其它文件与链接

指纹

引用此